Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
membrane glycoprotein\; acts as a synaptic vesicle-specific transporter [RGD, Feb 2006].. Additionally we are shipping SV2A Antibodies (44) and many more products for this protein.
Showing 5 out of 7 products:
This study reveals fundamental details of how phosphorylation of Thr84 on SV2A controls its interaction with synaptotagmin-1 (show SYT1 Proteins) and implicates SV2A as a phospho-dependent chaperone
observed alterations of SV2A expression in hippocampus are consistent with the hypothesis that SV2A absence favors epileptic seizures around postnatal day 7
Action potential- and Ca(2 (show CA2 Proteins)+) -dependent glutamatergic & GABAergic synaptic transmission are differentially altered in the hippocampus of SV2A-deficient mice, but the mechanism of exocytosis itself is not changed.
Glycosylation is dispensable for sorting of synaptotagmin 1 (show SYT1 Proteins) but is critical for targeting of SV2 and synaptophysin (show SYP Proteins) to recycling synaptic vesicles.
study suggests that SV2A specifically regulates hilar GABAergic neurotransmission in the kindled hippocampus probably as a compensatory or prophylactic mechanism against kindling epileptogenesis
Loss of synaptic vesicle glycoprotein 2a is associated with inhibition of tetanus neurotoxin into central neurons.
These results indicate that SV2 performs at least two actions at the synapse that contribute to neurotransmitter release.
SV2A is selectively localized in motor nerve terminals on slow (type I and small type IIA) muscle fibers.
SV2 action modulates synaptic networks by ensuring that low-frequency neurotransmission is faithfully conveyed.
findings show that botulinum neurotoxin (BoNT/A) enters neurons by binding to the synaptic vesicle protein SV2 (isoforms A, B, and C);SV2 acts as the protein receptor for BoNT/A
Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.
SV2A expression in the bladder urothelium increases after BoNT-A injection.
the way LEV analogues may interact with SV2A
agents that act on the conformation of SV2A might hold great potential in the search for new SV2A-based anticonvulsant therapies
The newly identified galactose transport capability of SV2A may have an important role in regulating/modulating synaptic function.
The SV2A/FE65 (show APBB1 Proteins) interaction might play a role in synaptic signal transduction.
In classical mesial temporal sclerosis 1A, the expression of SV2 isoforms is altered with a marked decrease of SV2A paralleling synaptic loss.
High SV2A expression is associated with breast cancer.
This study in the German population provides evidence, at a genetic level, for the involvement of the SV2A gene region in schizophrenia.
Data report a combined modelling and mutagenesis study that successfully identifies another 11 residues in synaptic vesicle protein 2A that appear to be involved in ligand binding.
membrane glycoprotein\; acts as a synaptic vesicle-specific transporter
synaptic vesicle glycoprotein 2
, synaptic vesicle glycoprotein 2A
, synaptic vesicle glycoprotein 2A-like
, calcium regulator SV2A
, synaptic vesicle protein 2
, synaptic vesicle protein 2A
, synaptic vesicle transmembrane transporter (SV2) RNA